Research programme: age-related macular degeneration therapy - Philogen
Alternative Names: L19-PDT; VangioluxLatest Information Update: 16 Jul 2016
At a glance
- Originator Philogen
- Class Antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Age-related macular degeneration
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in Italy
- 30 Mar 2010 Preclinical trials in Age-related macular degeneration in Italy (unspecified route)